Ken Griffin Soligenix, Inc. Transaction History

Citadel Advisors LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.4 - $168.0 $25,606 - $10.8 Million	64,015 New	64,015 $28,000
Q1 2022 May 16, 2022	SELL	$0.61 - $0.75 $12,989 - $15,971	-21,295 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$0.66 - $1.1 $129,563 - $215,938	-196,308 Reduced 90.21%	21,295 $14,000
Q3 2021 Nov 15, 2021	BUY	$0.9 - $1.31 $122,247 - $177,938	135,831 Added 166.11%	217,603 $231,000
Q2 2021 Aug 16, 2021	SELL	$0.87 - $1.58 $3,057 - $5,552	-3,514 Reduced 4.12%	81,772 $90,000
Q1 2021 May 17, 2021	BUY	$1.31 - $2.35 $111,724 - $200,422	85,286 New	85,286 $130,000
Q4 2020 Feb 16, 2021	SELL	$1.26 - $2.75 $26,849 - $58,599	-21,309 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$1.7 - $2.61 $16,690 - $25,624	9,818 Added 85.44%	21,309 $38,000
Q2 2020 Aug 14, 2020	SELL	$1.36 - $2.26 $26,258 - $43,636	-19,308 Reduced 62.69%	11,491 $24,000
Q2 2019 Aug 14, 2019	SELL	$0.67 - $0.91 $2,361 - $3,207	-3,525 Reduced 10.27%	30,799 $22,000
Q1 2019 May 15, 2019	BUY	$0.88 - $1.04 $17,839 - $21,082	20,272 Added 144.26%	34,324 $0
Q3 2018 Nov 13, 2018	SELL	$0.98 - $1.97 $5,602 - $11,262	-5,717 Reduced 28.92%	14,052 $0
Q1 2018 May 11, 2018	BUY	$1.92 - $2.4 $37,956 - $47,445	19,769 New	19,769 $39,000

Ticker SNGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,105,200
Market Cap $133M
Description
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has c...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.